Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
9 min read
Exelixis, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Exelixis, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
9 min read
Evopoint Biosciences Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Evopoint Biosciences Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationa
Latest Hotspot
9 min read
European Organisation for Research & Treatment of Cancer Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for European Organisation for Research & Treatment of Cancer: pipeline stage, evidence package, IP risk, deal precedent, financial si
Latest Hotspot
9 min read
Eurofarma Laboratórios SA Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Eurofarma Laboratórios SA: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
9 min read
Epi Biotech Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Epi Biotech Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
8 min read
Enveda Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Enveda Therapeutics, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
9 min read
Elpiscience (Suzhou) Biopharma, Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Elpiscience (Suzhou) Biopharma, Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach r
Latest Hotspot
9 min read
Eilean Therapeutics LLC Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Eilean Therapeutics LLC: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
9 min read
Eccogene (Shanghai) Co., Ltd Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Eccogene (Shanghai) Co., Ltd: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale
Latest Hotspot
9 min read
E-Nitiate Biopharmaceuticals Hangzhou Co. Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for E-Nitiate Biopharmaceuticals Hangzhou Co. Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and
Latest Hotspot
9 min read
Dyne Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Dyne Therapeutics, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
8 min read
Draig Therapeutics Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Draig Therapeutics Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.